Thus, the efficacy of BETi in NC treatment opens the possibility to extent the administration of these drugs to NUTM1 B-ALL patients to generate a unique therapeutic opportunity for this B-ALL subtype. This evidence concerns the gene NUTM1 and acute lymphoblastic leukemia.